BioNTech BNT142-01 (Solid Tumor Cancers with CLDN6 Protein)

We are doing this study to find out if an experimental drug called BNT142 (the study drug) is a safe and effective treatment for select cancers with solid tumors that test positive for a protein called Claudin 6 (CLDN6).

Solid Tumor Cancers that Express the Protein Claudin 6 (CLDN6)

Adults ages 18+ who:

• Are diagnosed with one of the following types of solid tumor cancers:
• Ovarian cancer; OR
• Non-small cell lung cancer; OR
• endometrial cancer; OR
• Testicular cancer
• Have received all available standard therapies for treatment
• Test positive for the presence of CLDN6

For more information about who can join this study, please contact the study team at 919-681-6468.

If you choose to join this study, you will:

• Have a tumor biopsy to test the tissue for CLDN6
• Receive the study drug through an intravenous (IV) infusion
• Have physical exams, blood draws, and give urine samples
• Have imaging scans (CT and/or MRI)
• Have heart tests (ECG)